Costunolide represses hepatic fibrosis through WW domain‐containing protein 2‐mediated Notch3 degradation

Abstract

COS exerted potent antifibrotic effects in vitro and in vivo by disrupting the WWP2/PPM1G complex, promoting Notch3 degradation and inhibiting the Notch3/HES1 pathway. This indicates that COS may be a potential therapeutic candidate for the treatment of liver fibrosis.